Marshall Urist Sells 9,098 Shares of Royalty Pharma (NASDAQ:RPRX) Stock

June 26, 2026 by InsiderTrades.com

Key Points

Royalty Pharma EVP Christopher Hite sold 150,000 shares on June 23 at an average price of $54.40, generating about $8.16 million. After the sale, he still held 559,399 shares, and the trade was made under a pre-arranged Rule 10b5-1 plan.
Royalty Pharma shares edged up 0.8% and recently traded near $54.69, close to the stock’s 52-week high of $56.50. The company now has a market cap of about $31.49 billion.
The company recently beat quarterly EPS estimates with earnings of $1.30 per share, though revenue came in below expectations. Royalty Pharma also paid a quarterly dividend of $0.235 per share, and analysts remain broadly positive with a consensus Buy rating.

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 9,098 shares of the company's stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $55.18, for a total transaction of $502,027.64. Following the completion of the transaction, the executive vice president owned 9,099 shares in the company, valued at approximately $502,082.82. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

How Royalty Pharma Prints Cash Without Biotech's Biggest Risks

Marshall Urist also recently made the following trade(s):

On Wednesday, May 20th, Marshall Urist sold 13,684 shares of Royalty Pharma stock. The stock was sold at an average price of $52.75, for a total transaction of $721,831.00.
On Thursday, May 14th, Marshall Urist sold 13,684 shares of Royalty Pharma stock. The stock was sold at an average price of $53.06, for a total value of $726,073.04.

Royalty Pharma Price Performance

Royalty Pharma stock opened at $54.69 on Friday. The company has a market capitalization of $31.49 billion, a price-to-earnings ratio of 37.20, a PEG ratio of 1.49 and a beta of 0.43. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. Royalty Pharma PLC has a 12 month low of $34.08 and a 12 month high of $56.50. The stock's 50 day moving average is $52.66 and its 200-day moving average is $46.52.

1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.08. The business had revenue of $630.58 million during the quarter, compared to analysts' expectations of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. Equities research analysts expect that Royalty Pharma PLC will post 5.05 EPS for the current year.

Royalty Pharma Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were given a $0.235 dividend. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend was Friday, May 15th. Royalty Pharma's payout ratio is presently 63.95%.

Institutional Trading of Royalty Pharma

4 Healthcare Stocks With Massive Gains—and More to Come

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Royal Bank of Canada increased its stake in Royalty Pharma by 367.7% in the first quarter. Royal Bank of Canada now owns 203,760 shares of the biopharmaceutical company's stock valued at $6,342,000 after acquiring an additional 160,191 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Royalty Pharma by 20.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,990 shares of the biopharmaceutical company's stock worth $2,490,000 after buying an additional 13,489 shares in the last quarter. Focus Partners Wealth bought a new stake in shares of Royalty Pharma during the 1st quarter worth $264,000. Intech Investment Management LLC lifted its position in shares of Royalty Pharma by 41.0% during the 1st quarter. Intech Investment Management LLC now owns 47,992 shares of the biopharmaceutical company's stock worth $1,494,000 after buying an additional 13,951 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in Royalty Pharma by 21.4% in the second quarter. Invesco Ltd. now owns 1,559,378 shares of the biopharmaceutical company's stock valued at $56,184,000 after buying an additional 274,960 shares in the last quarter. Institutional investors own 54.35% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on RPRX. Citigroup raised their price target on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a "buy" rating in a research report on Thursday, May 7th. TD Cowen restated a "buy" rating on shares of Royalty Pharma in a research report on Friday, February 27th. Wall Street Zen raised shares of Royalty Pharma from a "buy" rating to a "strong-buy" rating in a report on Saturday, May 9th. Weiss Ratings downgraded shares of Royalty Pharma from a "buy (b)" rating to a "buy (b-)" rating in a research report on Friday, May 15th. Finally, JPMorgan Chase & Co. boosted their price target on Royalty Pharma from $50.00 to $58.00 and gave the company an "overweight" rating in a research note on Thursday, May 7th. Seven investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $53.71.

Check Out Our Latest Research Report on RPRX

Royalty Pharma Company Profile

(Get Free Report)

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.